Zim Labs Q1 FY27 Results: Consolidated Net Loss Widens to ₹4.02 Cr
Zim Laboratories Limited reported unaudited financial results for Q1 FY27. Consolidated revenue increased to ₹94.18 crore from ₹71.76 crore YoY. However, consolidated net loss widened to ₹4.02 crore from ₹1.87 crore. Standalone revenue grew to ₹93.05 crore from ₹71.43 crore, with a standalone net loss of ₹3.88 crore.
The widening net loss, even with revenue growth, indicates potential margin pressures or increased costs, which could impact investor sentiment. However, the revenue growth is a positive sign, making the impact medium rather than high.
The company reported a wider net loss on a consolidated basis compared to the same period last year, despite an increase in revenue. The standalone results also show a significant net loss.
Zim Laboratories Limited announced its unaudited financial results for the quarter ended June 30, 2026. The company's consolidated revenue from operations stood at ₹9,417.85 lakhs, a notable increase from ₹7,175.61 lakhs in the same period last year. However, total expenses rose to ₹10,074.38 lakhs from ₹7,566.44 lakhs.
This led to a consolidated loss before tax of ₹557.30 lakhs, compared to a loss of ₹243.20 lakhs in the prior year's quarter. After accounting for tax expenses, the consolidated net loss after tax for the quarter widened to ₹401.70 lakhs (approximately ₹4.02 crore), an increase from the ₹187.49 lakhs loss reported in the quarter ended June 30, 2025.
On a standalone basis, revenue from operations for the quarter was ₹9,304.83 lakhs, up from ₹7,142.77 lakhs in the corresponding quarter of the previous year. Standalone expenses were ₹9,945.60 lakhs. The company reported a standalone loss before tax of ₹542.22 lakhs, and a net loss after tax of ₹387.55 lakhs for the quarter ended June 30, 2026. This compares to a standalone net loss of ₹169.19 lakhs in the same period last year.
The Board of Directors approved these unaudited financial results, which were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors, Deloitte Haskins & Sells LLP. The financial results were prepared in accordance with Indian Accounting Standards (Ind AS) and SEBI regulations. The Board meeting commenced at 10:30 a.m. IST and concluded at 01:50 p.m. IST on August 6, 2026.
What to do with a filing like this
Zim Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zim Laboratories Limited. Read the original for the full detail.